Biosimilar Biologic Drugs: A Systematic Approach to Development, Manufacturing and Clinical Applications

  • Kaiser Jay Aziz-Andersen Director, Grand Medical Institute, Bowie, Maryland, USA

Abstract

This publication addresses biosimilar biologic drugs development and future innovations. Emphasis is placed on quality system approaches to the development and availability of new biosimilar drug products presented in premarket applications. For approvals of new biosimilars, the sponsors of premarket applications must present analytical and biological characterization to demonstrate that a proposed biosimilar drug is highly similar to the licensed reference product. The premarket application protocol requires a sponsor to describe the biosimilar product’s PK/PD clinical data comparing its safety, efficacy, and immunogenicity to that of the licensed reference product. Emphasis is placed on Quality by Design (QbD), Validation, Verification, and c-GMP risk-based monitoring criteria. A brief discussion is presented on risk-benefit assessment that guides the clinical use of the new biosimilar drug product by providing patients organized data and appropriate labeling information in conformance with the new biosimilar drug’s intended clinical use.


Keywords: biosimilar biologic drugs, safety, efficacy and immunogenicity, Quality by Design (QbD)

Keywords: biosimilar biologic drugs, safety, efficacy and immunogenicity, Quality by Design (QbD)

Downloads

Download data is not yet available.

Author Biography

Kaiser Jay Aziz-Andersen, Director, Grand Medical Institute, Bowie, Maryland, USA

Director, Grand Medical Institute, Bowie, Maryland, USA

References

1. Aziz, KJ., Biosimilar drug development and approval process. J. Pharmacut Sci & Emerging Drugs. 2019; 7(2):1-5
2. Aziz, KJ., Biosimilars: The Process and Quality System Approach to Clinical Applications. Drug Development & Delivery. 2020; 20:5:1-7
3. Aziz, KJ., The FDAs New Drug Appeoval Process: Development and Premarket Applications. Drug Development & Delivery. 2016; 3:50-56
4. Aziz, KJ., The FDAs New Drug Approval Process: Development and Clinical Applications. Drug Development & Delivery. 2018; 4:1-10
5. Aziz, KJ., Pharmaceutical Manufacturing and Risk Management using Global HACCP Principles and Techniques. 2008, First and 4th Editions, Medical HACCP Alliance- Virginia Polytechnic Institute and State University, Blacksburg, VA
6. Lee, SL., et al., Modernizing Pharmaceutical Manufacturing from Batch to Continuous Production. J. Pharm Innovation. 2015; 10(3):191-199
7. U.S. Food and Drug Administration: Pharmaceutical cGMPs for the 21st Century- A Risk Based Approach. https://www.fda.gov/downloads/Drugs/Developmentapprovalprocess/manufacturing/questionsandanswers-practicesgmpfordrugs/ucm176374.pdf.Published Sept. 2004.Accessed January 8, 2019
8. Tesser J., et al., Biosimilars and the Extrapolation of Indications for inflammatory conditions. Biologics; 2017; 11:5-11
9. Yu, LX., et al., Understanding Pharmaceutical Quality by Design. AAPS J.; 2014; 16(4):771-83
10. Singh SR, et l., Effect of Polysorbate 80 – Quality of Photostability of a monoclonal antibody. AAPS Pharm Sci Tech. 2012; 13(2):422-430
Statistics
39 Views | 37 Downloads
How to Cite
1.
Aziz-Andersen KJ. Biosimilar Biologic Drugs: A Systematic Approach to Development, Manufacturing and Clinical Applications. JDDT [Internet]. 15Nov.2020 [cited 26Nov.2020];10(6):191-4. Available from: http://jddtonline.info/index.php/jddt/article/view/4373